Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma
NCT00887107
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Thyroid Cancer
Interventions
DRUG:
Sorafenib (nexavar)
Sponsor
Leiden University Medical Center